China-based Therorna Inc., a biotech company specializing in cutting-edge circular RNA (circRNA) technology for next-generation vaccines and therapies, has completed a Series A financing round exceeding RMB 280 million (USD 41.8 million). The round was led by a well-known industrial investment firm and MSA Capital, with participation from Sherpa Healthcare Partners, 3H Health Investment, and existing investors Quan Capital and Cenova Capital.
Funding Utilization
The proceeds from this financing will be used to accelerate the development of Therorna’s technology platform, advance its product pipeline, and support clinical trials, regulatory applications, and international collaborations. This significant investment underscores the confidence of investors in Therorna’s innovative approach to vaccine and therapy development.
Company Background
Founded in Beijing in 2021, Therorna has established a robust pipeline of novel prophylactic and therapeutic drugs leveraging its proprietary circRNA technology. The company is focused on addressing high unmet medical needs through its innovative platform.
Financial Milestones
To date, Therorna has raised a total of RMB 400 million (USD 59.7 million) across three financing rounds, including the recently closed angel and Pre-Series A rounds. This substantial funding reinforces Therorna’s position at the forefront of circRNA-based therapeutic development.-Fineline Info & Tech
